Atsushi Ishida

Atsushi Ishida

Auto-generated profile, based on publicly available information

Atsushi Ishida

Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Neurosurgery
Verified
Journal Article
Closed access
AIAtsushi Ishida
Atsushi Ishida
HSHideki Shiramizu
Hideki Shiramizu
HYHaruko Yoshimoto
Haruko Yoshimoto
MKMasataka Kato
Masataka Kato
NINaoko Inoshita
Naoko Inoshita
SYShozo Yamada
Shozo Yamada
BACKGROUND: The purpose of transsphenoidal surgery (TSS) for a functioning pituitary tumor (FPT) is to achieve endocrinological remission. The biggest challenge is aggressive tumor resection invading the cavernous sinus (CS). OBJECTIVE: To evaluate the effects of the medial wall of CS (MWCS) resection during FPT surgery. METHODS: Consecutive FPTs were reviewed for CS invasion (CSI) between April 2018 and December 2021. We operated on more than 250 FPTs, including 134 somatotroph tumors, 70 corticotroph tumors, 35 lactotroph tumors, and 9 thyrotroph tumors. RESULTS: The patients were classified into 3 groups based on the relationship between the tumor and the CS: group A (no clear wall invasion), in which MWCS was not removed because of no tumorous direct contact with MWCS (N = 92) and group B (possible wall invasion), where MWCS was removed because we were not confident of MWCS invasion (N = 102). Among these 102 patients, histological tumor invasion was confirmed in 45 of 79 patients (57%) for whom histology findings were available. Tumors invading the CS clearly during surgery were classified into the “clear CS invasion” (group C: N = 55) group. The overall complete remission rate in group B was 94%, which was as high as that in group A (87%). Moreover, we clarified that microscopic invasion of MWCS could not always be predicted from Knosp grading. CONCLUSION: MWCS invasion occurred in 57% of cases confirmed histologically where it was unclear during surgery, and its resection can improve the overall complete remission rate in FPT cases.

1 December 2023 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
AIAtsushi Ishida
Atsushi Ishida
KKKoichiro Kaneko
Koichiro Kaneko
RMRyogo Minamimoto
Ryogo Minamimoto
MHMasatoshi Hotta
Masatoshi Hotta
NINaoko Inoshita
Naoko Inoshita
SYShozo Yamada
Shozo Yamada
OBJECTIVE: Diagnosis and accurate localization of recurrent tumors in Cushing’s disease (CD) are challenging, especially after multiple transsphenoidal surgeries (TSSs) or radiosurgery. Even experts face difficulties in detecting these recurrent tumors, and a favorable surgical outcome is not guaranteed. In this report, the authors aimed to determine the usefulness of 11C-methionine positron emission tomography (MET-PET) for evaluating patients with recurrent CD with inconclusive magnetic resonance imaging (MRI) lesions and to develop a treatment protocol for these cases. METHODS: In this retrospective study of patients with recurrent CD in the period between April 2018 and December 2022, the authors assessed the usefulness of MET-PET in determining whether equivocal MRI findings were recurrent tumors or postsurgical cavities and deciding further treatment options. All patients had undergone at least one TSS, and most had undergone multiple TSSs and had pathologically confirmed corticotroph tumors with hypercortisolemia. RESULTS: Overall, 15 patients with recurrent CD (10 females and 5 males) were included, all of whom had undergone MET-PET. All patients had been subjected to multiple treatments, including TSSs or radiosurgeries. Their MRI scans demonstrated less-enhanced lesions that were not confirmed as recurrences even with cutting-edge MRI because they could not be distinguished from postsurgical changes with confidence. MET uptake was positive in 8 patients (9 examinations) and negative in 7. Following MET-PET, repeat TSS was performed in 5 patients. Corticotroph tumors were identified in all 5 patients, even though one of them had negative MET uptake. The MET uptake precisely identified a tumor location on the opposite side of the MRI-suspected lesion in 2 patients. Meanwhile, patients with negative uptake and mild hypercortisolism were only observed. Nonsurgical options were also used in other patients: temozolomide (TMZ) was administered in 2 patients owing to a prior history of multiple TSSs and radiosurgery and the drug-resistant nature of the disease. TMZ was highly effective in these patients; their Cushing’s symptoms ameliorated, and their adrenocorticotropic hormone and cortisol levels continued to decline. Interestingly, MET uptake disappeared following TMZ treatment. CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.

26 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
AIAtsushi Ishida
Atsushi Ishida
HSHiroki Shichi
Hiroki Shichi
HFHidenori Fukuoka
Hidenori Fukuoka
HSHideki Shiramizu
Hideki Shiramizu
NINaoko Inoshita
Naoko Inoshita
SYShozo Yamada
Shozo Yamada
Aggressive somatotroph pituitary tumor that causes acromegaly is extremely rare and resists conventional treatments such as multiple surgeries, radiotherapies, and various types of somatostatin analogs. Here, we propose a novel treatment option for these rare cases by discussing our case and reviewing the literature. We experienced an aggressive somatotroph tumor in a 52-year-old woman with acromegaly. Not only could a complete remission of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) not be obtained, but the tumor continued to grow and eventually recurred around the brainstem despite multidisciplinary treatments. We employed immunohistochemistry and a three-dimensional (3D) spheroid ex vivo assay to determine the best treatment option for this case. Although histology showed strong O6-methylguanine DNA methyltransferase expression and high Ki-67 labeling index (22%), temozolomide (TMZ) combined with capecitabine (CAPTEM) treatment was performed based on the results of the patient-derived 3D spheroid ex vivo assay, which predicted more effective treatment with CAPTEM than with TMZ alone. Consequently, GH and IGF-1 levels were restored to normal range with remarkable tumor shrinkage after CAPTEM treatment. To the best of our knowledge, there have been even very few reports describing successful treatment for such aggressive and refractory somatotroph tumors and this is the first report showing the effectiveness of CAPTEM on refractory somatotroph tumor both ex vivo and in vivo.

9 April 2013 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
HSHideki Shiramizu
Hideki Shiramizu
THTomokatsu Hori
Tomokatsu Hori
SMSeigo Matsuo
Seigo Matsuo
KNKaku Niimura
Kaku Niimura
HYHaruko Yoshimoto
Haruko Yoshimoto
TMTakashi Moriyama
Takashi Moriyama

1 January 2014 in Surgical Neurology International
Verified
Journal Article
Open access
HYHaruko Yoshimoto
Haruko Yoshimoto
HSHideki Shiramizu
Hideki Shiramizu
KNKaku Niimura
Kaku Niimura
MYMiki Yuzawa
Miki Yuzawa
YYYasumichi Yamagishi
Yasumichi Yamagishi
THTomokatsu Hori
Tomokatsu Hori
We previously reported a case of cerebral infarction complicated by myocardial infarction. The pathogenesis of both infarctions was thought to be vasospasm; thus, we named this condition 'idiopathic carotid and coronary vasospasm'. Various medical treatments for the prevention of carotid vasospasm have been unsuccessfully tried. Thus, other effective treatments should be established for patients who frequently suffer cerebral ischemic attacks. We treated the present case of 'idiopathic carotid and coronary vasospasm' by carotid artery stenting (CAS). The first stenting, of the carotid bifurcation, failed to prevent internal carotid artery (ICA) vasospasm. However, after an additional stent placement to the prepetrous portion, ischemic attacks were dramatically reduced. The effect of CAS for extracranial ICA vasospasm was dramatic and control of the spasm at the prepetrous portion seems to be essential. Further validation of the effectiveness and safety of CAS for ICA vasospasm will be necessary.

1 May 2007 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
HKHiroki Kohno
Hiroki Kohno
AIAtsushi Ishida
Atsushi Ishida
MIMizuho Imamaki
Mizuho Imamaki
HSHitoshi Shimura
Hitoshi Shimura
Masaru MiyazakiMasaru Miyazaki
Masaru Miyazaki